Lipocine
LPCN
38 hedge funds and large institutions have $10M invested in Lipocine in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 2 closing their positions.
646% more call options, than puts
Call options by funds: $1.68M | Put options by funds: $225K
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
19% more funds holding
Funds holding: 32 → 38 (+6)
0% more ownership
Funds ownership: 0.61% → 0.61% (+0%)
22% less capital invested
Capital invested by funds: $12.8M → $10M (-$2.76M)
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$465K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$262K |
| 3 |
PVI
Pura Vida Investments
New York
|
-$77K |
| 4 |
Bank of New York Mellon
New York
|
-$71.4K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $18K | – | – | – |
|
|
CG
27
Cutler Group
San Francisco,
California
| $14K | – | – | – |
|
28
Creative Planning
Overland Park,
Kansas
| $11K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $8K | +$9.82K | +445 | New |
|
30
Wells Fargo
San Francisco,
California
| $5K | +$3.86K | +175 | +261% |
|
31
JP Morgan Chase
New York
| $3K | – | – | – |
|
32
UBS Group
Zurich,
Switzerland
| $2K | -$6.11K | -277 | -69% |
|
|
BFEC
33
Benjamin F. Edwards & Company
St. Louis,
Missouri
| $2K | – | – | – |
|
34
Bank of America
Charlotte,
North Carolina
| $2K | +$1.46K | +66 | +108% |
|
|
SWA
35
Sutton Wealth Advisors
Tampa,
Florida
| $1.09K | – | – | – |
|
|
GWMIA
36
Global Wealth Management Investment Advisory
Fort Lauderdale,
Florida
| $1K | – | – | – |
|
|
PWM
37
Prentice Wealth Management
Rochester,
New York
| $1K | – | – | – |
|
|
PVI
38
Pura Vida Investments
New York
| – | -$77K | -3,220 | Closed |
|
|
39
Charles Schwab
San Francisco,
California
| – | -$52K | -2,153 | Closed |
|
40
Fidelity Investments
Boston,
Massachusetts
| – | +$243 | +11 | New |
|
LPCN Hedge Fund Activity: Q3 2021 in Review
38 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2021, worth a combined $10M — down 22% from $12.8M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LPCN positions and 2 closed out — a net gain of 6 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Kestra Advisory Services, adding an estimated $233K. The largest seller was Morgan Stanley, cutting an estimated $465K.
- 38 institutional investors held Lipocine (LPCN) as of Q3 2021, up from 32 in Q2 2021.
- Funds reported $10M of Lipocine stock for Q3 2021, down 22% quarter-over-quarter.
- 8 funds opened new Lipocine positions in Q3 2021 and 2 closed out, a net change of +6 holders.
- The largest Lipocine buyer in Q3 2021 was Kestra Advisory Services, an estimated $233K added.
- The largest Lipocine seller in Q3 2021 was Morgan Stanley, an estimated $465K sold.
Based on aggregated 13F filings for Q3 2021.